Read by QxMD icon Read

European Journal of Cancer

Melissa Vos, Harriët G T Blaauwgeers, Vincent K Y Ho, Winan J van Houdt, Jos A van der Hage, Lukas B Been, Johannes J Bonenkamp, Marc H A Bemelmans, Thijs van Dalen, Rick L Haas, Dirk J Grünhagen, Cornelis Verhoef
BACKGROUND: Diagnosing and treating soft tissue sarcomas (STSs) remains challenging, stressing the urgency for centralisation. This nationwide survey aimed to evaluate the centralisation of STS surgery and its effect on survival. METHODS: Patients operated for primary STS from 2006 to 2015 were queried from the Netherlands Cancer Registry. Hospitals in which STS surgery was performed were allocated into three categories: low-volume (1-9 resections per year), medium-volume (10-19 resections) or high-volume (≥20 resections)...
February 15, 2019: European Journal of Cancer
Francesca Bagnasco, Silvia Caruso, Anita Andreano, Maria Grazia Valsecchi, Momcilo Jankovic, Andrea Biondi, Lucia Miligi, Claudia Casella, Monica Terenziani, Maura Massimino, Carlotta Sacerdote, Vera Morsellino, Giovanni Erminio, Alberto Garaventa, Maura Faraci, Concetta Micalizzi, Maria Luisa Garrè, Marta Pillon, Giuseppe Basso, Eleonora Biasin, Franca Fagioli, Roberto Rondelli, Andrea Pession, Franco Locatelli, Nicola Santoro, Paolo Indolfi, Giovanna Palumbo, Giovanna Russo, Federico Verzegnassi, Claudio Favre, Marco Zecca, Rossella Mura, Paolo D'Angelo, Carmen Cano, Julianne Byrne, Riccardo Haupt
INTRODUCTION: Advances in paediatric oncology led to the increase in long-term survival, revealing the burden of therapy-related long-term side effects. We evaluated overall and cause-specific mortality in a large cohort of Italian childhood cancer survivors (CCSs) and adolescent cancer survivors identified through the off-therapy registry. MATERIALS AND METHODS: CCSs alive 5 years after cancer diagnosis occurring between 1960 and 1999 were eligible; the last follow-up was between 2011 and 2014...
February 14, 2019: European Journal of Cancer
Andrew D J Pearson, Nicole Scobie, Koenraad Norga, Franca Ligas, Davy Chiodin, Amos Burke, Veronique Minard-Colin, Peter Adamson, Lynley V Marshall, Arun Balakumaran, Bouchra Benettaib, Pankaj Bhargava, Catherine M Bollard, Ellen Bolotin, Simon Bomken, Jochen Buechner, Birgit Burkhardt, Hubert Caron, Christopher Copland, Pierre Demolis, Anton Egorov, Mahdi Farhan, Gerhard Zugmaier, Thomas Gross, Danielle Horton-Taylor, Wolfram Klapper, Giovanni Lesa, Robert Marcus, Rodney R Miles, Kerri Nottage, Lida Pacaud, Rosanna Ricafort, Martin Schrappe, Jaroslav Sterba, Remus Vezan, Susan Weiner, Su Young Kim, Gregory Reaman, Gilles Vassal
Paediatric Strategy Forums have been created by the multistakeholder organisation, ACCELERATE, and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and suggest strategies in critical areas of paediatric oncology drug development. As there are many medicines being developed for B-cell malignancies in adults but comparatively few in children with these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop these products for children. It was concluded that as current frontline therapy is highly successful, despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with new medicines can only be undertaken when there is an effective salvage regimen, which is currently not available...
February 14, 2019: European Journal of Cancer
Tony Ibrahim, Clovis Adam, Emilie Routier, Abdelhamid Slama, Caroline Robert
No abstract text is available yet for this article.
February 14, 2019: European Journal of Cancer
W van Boxtel, L D Locati, A C H van Engen-van Grunsven, C Bergamini, M A Jonker, E Fiets, S Cavalieri, S Tooten, E Bos, P Quattrone, C M L van Herpen
AIM: Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)-positive in 67-96% of cases. In patients with locally recurrent and metastatic (R/M) AR-positive SDC, androgen deprivation therapy (ADT) has an overall response rate of 18-64.7%. In this study, we describe the efficacy of adjuvant ADT in patients with poor-risk (stage 4a) AR-positive SDC. METHODS: This is a retrospective cohort study in which patients with stage 4a AR-positive SDC were offered adjuvant ADT, i...
February 13, 2019: European Journal of Cancer
M Ekholm, P O Bendahl, M Fernö, B Nordenskjöld, O Stål, L Rydén
AIMS: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER)-positive tumours, regarding breast cancer-free interval (BCFi) and distant recurrence-free interval (D-RFi), with 30 years of follow-up and for specified intervals. Moreover, we aimed to investigate the effects of adjuvant tamoxifen on the incidence of secondary malignancies and survival after distant recurrence. METHODS: Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n = 277) or no systemic treatment (n = 287), irrespective of ER status...
February 12, 2019: European Journal of Cancer
Mathilde Berger, Mona Amini-Adlé, Laura Crumbach, Etienne Paubelle, Stéphane Dalle
No abstract text is available yet for this article.
February 7, 2019: European Journal of Cancer
Therese M-L Andersson, Gerda Engholm, Anne-Sofie Q Lund, Sofia Lourenço, Jeppe Matthiessen, Eero Pukkala, Magnus Stenbeck, Laufey Tryggvadottir, Elisabete Weiderpass, Hans Storm
BACKGROUND: Physical activity has been shown to reduce the risk of colon, endometrial and postmenopausal breast cancer. The aim of this study was to quantify the proportion of the cancer burden in the Nordic countries linked to insufficient levels of leisure time physical activity and estimate the potential for cancer prevention for these three sites by increasing physical activity levels. METHODS: Using the Prevent macrosimulation model, the number of cancer cases in the Nordic countries over a 30-year period (2016-2045) was modelled, under different scenarios of increasing physical activity levels in the population, and compared with the projected number of cases if constant physical activity prevailed...
February 7, 2019: European Journal of Cancer
Gianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, Sara Lonardi, Piero Buccianti, Aldo Sainato, Lorenzo Marcucci, Angelo Martignetti, Emanuele Damiano Luca Urso, Maura Castagna, Gabriella Fontanini, Francesca Bergamo, Gianna Musettini, Lucio Urbani, Elisa Sensi, Riccardo Balestri, Sabrina Montrone, Francesco Pasqualetti, Chiara Cremolini, Antonello Di Paolo, Vittorina Zagonel, Alfredo Falcone
BACKGROUND: Neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) does not achieve effective control of distant metastases. Induction chemotherapy is a promising strategy, and bevacizumab (BV) could improve the results of CRT. 5-Fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) plus BV is a treatment option in metastatic colorectal cancer. We evaluate feasibility and efficacy of neoadjuvant treatment comprising induction FOLFOXIRI plus BV followed by CRT with fluoropyrimidines plus BV...
February 7, 2019: European Journal of Cancer
Xiao-Yun Li, Qiu-Yan Chen, Xue-Song Sun, Sai-Lan Liu, Jin-Jie Yan, Shan-Shan Guo, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Yue-Feng Wen, Ling Guo, Hao-Yuan Mo, Ming-Yuan Chen, Ying Sun, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai
PURPOSE: Our previous results showed survival benefits of concurrent chemoradiotherapy (CCRT) in treating stage II nasopharyngeal carcinoma (NPC) compared with radiotherapy (RT) alone. Here, we present the updated 10-year survival results and late toxicity profile to assess the ultimate effectiveness of concurrent chemotherapy. METHODS: Patients with stage II NPC were randomly assigned to RT arm (n = 114) or to CCRT arm (n = 116) with a concurrent weekly cisplatin regimen...
February 7, 2019: European Journal of Cancer
Martin Dutertre, Mathilde de Menthon, Nicolas Noël, Laurence Albiges, Olivier Lambotte
No abstract text is available yet for this article.
February 7, 2019: European Journal of Cancer
Ricarda Rauschenberg, Johannes Bruns, Julia Brütting, Dirk Daubner, Fabian Lohaus, Lisa Zimmer, Andrea Forschner, Daniel Zips, Jessica C Hassel, Carola Berking, Katharina C Kaehler, Jochen Utikal, Ralf Gutzmer, Patrik Terheyden, Frank Meiss, David Rafei-Shamsabadi, Felix Kiecker, Dirk Debus, Evelyn Dabrowski, Andreas Arnold, Marlene Garzarolli, Marvin Kuske, Stefan Beissert, Steffen Löck, Jennifer Linn, Esther G C Troost, Friedegund Meier
BACKGROUND: Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs) achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) in retrospective analyses. However, several aspects of this treatment strategy remain poorly understood. We report on the overall survival (OS) of patients with MBM treated with a combination of radiotherapy (RT) and ST as well as the impact of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)-V600 mutation (BRAFmut) status, types of RT and ST and their sequence...
February 7, 2019: European Journal of Cancer
Zhen Wang, Cheng Huang, Jin-Ji Yang, Yong Song, Ying Cheng, Gong-Yan Chen, Hong-Hong Yan, Xiao-Song Ben, Bin-Chao Wang, Chong-Rui Xu, Ben-Yuan Jiang, Qing Zhou, Hua-Jun Chen, Yi-Long Wu
BACKGROUND: Nab-paclitaxel/carboplatin (nab-PC) and gemcitabine/carboplatin (GC) are the standard first-line chemotherapy in non-small cell lung carcinoma. Up to now, there is no head to head trial to compare nab-PC with GC in advanced squamous cell lung carcinoma. PATIENTS AND METHODS: A multicentre randomised phase II trial was performed to compare the efficacy and safety for nab-PC with GC in previously untreated patients with advanced squamous cell lung carcinoma...
February 7, 2019: European Journal of Cancer
Kaitlyn Johnson, Axel Gomez, Jackson Burton, Douglas White, Arijit Chakravarty, Annette Schmid, Dean Bottino
AIM: We seek to characterize how faster tumour shrinkage rate (k) can lead to paradoxically shorter Response Evaluation Criteria in Solid Tumors (RECIST) time to progression ('TTP20' - tumour size exceeding its minimum by 5 mm and 20%) [1] and, therefore, progression-free survival (PFS). Specifically, we investigate under what conditions this paradoxical behaviour occurs, what fraction of patients satisfy these conditions, whether this phenomenon can invert population-level PFS hazard ratio, and consistency of an alternative time-to-event benefit metric with k...
February 6, 2019: European Journal of Cancer
Chiara Cremolini, Federica Marmorino, Francesca Bergamo, Giuseppe Aprile, Lisa Salvatore, Gianluca Masi, Emanuela Dell'Aquila, Carlotta Antoniotti, Sabina Murgioni, Giacomo Allegrini, Beatrice Borelli, Donatello Gemma, Mariaelena Casagrande, Cristina Granetto, Sara Delfanti, Samantha Di Donato, Marta Schirripa, Elisa Sensi, Giuseppe Tonini, Sara Lonardi, Gabriella Fontanini, Luca Boni, Alfredo Falcone
BACKGROUND: Alternating induction and maintenance phases is a common strategy in metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a well-tolerated chemotherapy backbone for maximising bevacizumab effect during maintenance. The MOMA trial was designed to compare metroCT plus bevacizumab versus bevacizumab alone as maintenance following 4 months of induction with FOLFOXIRI plus bevacizumab. PATIENTS AND METHODS: In this phase II study, patients with unresectable mCRC were randomised to receive up to 8 cycles of FOLFOXIRI plus bevacizumab, followed by bevacizumab (arm A) or the same regimen followed by bevacizumab plus metroCT (capecitabine 500 mg/three times per day and cyclophosphamide 50 mg/die, arm B) until disease progression...
February 5, 2019: European Journal of Cancer
Davide Fattore, Luigia Panariello, Maria Carmela Annunziata, Gabriella Fabbrocini
No abstract text is available yet for this article.
February 5, 2019: European Journal of Cancer
N Grössmann, M Robausch, K Rosian, C Wild, J Simon
OBJECTIVE: The introduction provisional approval strategies increases the approval of anticancer drugs with ambiguous benefit-risk profiles. Thus, in many instances, there is lacking evidence about overall survival (OS) at the time of marketing authorisation. Our objective was to monitor and characterise therapies with ambiguous benefit-risk profiles and identify any postapproval updates on median OS after at least 3 years of approval by the European Medicines Agency (EMA). METHODS: We included all originator anticancer drugs with initially ambiguous benefit-risk profiles that received marketing authorisation by the EMA between January 1, 2009 and May 31, 2015...
February 5, 2019: European Journal of Cancer
Juliette Gueguen, Elodie Bailly, Laurent Machet, Elodie Miquelestorena-Standley, Karl Stefic, Philippe Gatault, Matthias Büchler
No abstract text is available yet for this article.
February 4, 2019: European Journal of Cancer
M M Frijstein, C A R Lok, D Short, K Singh, R A Fisher, B W Hancock, J A Tidy, N Sarwar, E Kanfer, M C Winter, P M Savage, M J Seckl
OBJECTIVE: The objective of the study was to evaluate the effect of high-dose chemotherapy (HDC) with peripheral blood stem cell support (PBSCS) on survival of patients with gestational trophoblastic neoplasia (GTN) with either refractory choriocarcinomas or a poor-prognosis placental site/epithelioid trophoblastic tumours (PSTT/ETTs). METHODS: Databases of two referral centres for gestational trophoblastic disease were searched, and 32 patients treated with HDC between 1994 and 2015 were identified...
February 4, 2019: European Journal of Cancer
Neil H Segal, Sai-Hong I Ou, Ani Balmanoukian, Matthew G Fury, Erminia Massarelli, Julie R Brahmer, Jared Weiss, Patrick Schöffski, Scott J Antonia, Christophe Massard, Dan P Zandberg, Samir N Khleif, Feng Xiao, Marlon C Rebelatto, Keith E Steele, Paul B Robbins, Natasha Angra, Xuyang Song, Shaad Abdullah, Marcus Butler
INTRODUCTION: Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety were reported in urothelial carcinoma, non-small-cell lung cancer (NSCLC), hepatocellular carcinoma (HC) and small-cell lung cancer (SCLC) in a multicenter phase I/II study. Safety and clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) were evaluated in the expansion phase. METHODS: Patients received 10 mg/kg of durvalumab intravenously every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity...
February 4, 2019: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"